• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疟疾:控制、诊断、治疗的现状以及拟议的研发议程

Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development.

作者信息

Guerin Philippe J, Olliaro Piero, Nosten Francois, Druilhe Pierre, Laxminarayan Ramanan, Binka Fred, Kilama Wen L, Ford Nathan, White Nicholas J

机构信息

Norwegian Institute of Public Health, Norway.

出版信息

Lancet Infect Dis. 2002 Sep;2(9):564-73. doi: 10.1016/s1473-3099(02)00372-9.

DOI:10.1016/s1473-3099(02)00372-9
PMID:12206972
Abstract

Rolling back malaria is possible. Tools are available but they are not used. Several countries deploy, as their national malaria control treatment policy, drugs that are no longer effective. New and innovative methods of vector control, diagnosis, and treatment should be developed, and work towards development of new drugs and a vaccine should receive much greater support. But the pressing need, in the face of increasing global mortality and general lack of progress in malaria control, is research into the best methods of deploying and using existing approaches, particularly insecticide-treated mosquito nets, rapid methods of diagnosis, and artemisinin-based combination treatments. Evidence on these approaches should provide national governments and international donors with the cost-benefit information that would justify much-needed increases in global support for appropriate and effective malaria control.

摘要

遏制疟疾是有可能的。相关工具已经具备,但未得到使用。一些国家将不再有效的药物作为其国家疟疾控制治疗政策来部署。应开发新的、创新性的病媒控制、诊断和治疗方法,并且致力于新药和疫苗研发的工作应获得更多支持。然而,面对全球死亡率上升以及疟疾控制普遍缺乏进展的情况,当务之急是研究部署和使用现有方法的最佳方式,特别是经杀虫剂处理的蚊帐、快速诊断方法以及以青蒿素为基础的联合治疗。关于这些方法的证据应向各国政府和国际捐助方提供成本效益信息,从而证明全球急需增加对适当且有效的疟疾控制的支持是合理的。

相似文献

1
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development.疟疾:控制、诊断、治疗的现状以及拟议的研发议程
Lancet Infect Dis. 2002 Sep;2(9):564-73. doi: 10.1016/s1473-3099(02)00372-9.
2
Malaria in children.儿童疟疾。
Lancet. 2010 Apr 24;375(9724):1468-81. doi: 10.1016/S0140-6736(10)60447-3.
3
Cost-effectiveness of malaria control in sub-Saharan Africa.撒哈拉以南非洲地区疟疾防控的成本效益
Lancet. 1999 Jul 31;354(9176):378-85. doi: 10.1016/s0140-6736(99)02141-8.
4
Putting malaria in pregnancy back in the spotlight.让孕期疟疾问题重新成为焦点。
Lancet Infect Dis. 2018 Apr;18(4):371-372. doi: 10.1016/S1473-3099(18)30067-7. Epub 2018 Jan 31.
5
Malaria.疟疾。
Lancet. 2018 Apr 21;391(10130):1608-1621. doi: 10.1016/S0140-6736(18)30324-6. Epub 2018 Apr 6.
6
malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.疟疾消除与根除的诊断、药物、疫苗及病媒控制的最新研究议程:疟疾消除与根除研究议程更新版(malERA)
PLoS Med. 2017 Nov 30;14(11):e1002455. doi: 10.1371/journal.pmed.1002455. eCollection 2017 Nov.
7
Learning to outwit malaria.学习智取疟疾。
Bull World Health Organ. 2011 Jan 1;89(1):10-1. doi: 10.2471/BLT.11.040111.
8
[On the way to eradicating malaria].[在根除疟疾的道路上]
Ned Tijdschr Geneeskd. 2012;156(5):A4095.
9
Do we still need a malaria vaccine?我们仍然需要疟疾疫苗吗?
Parasite Immunol. 2009 Sep;31(9):582-6. doi: 10.1111/j.1365-3024.2009.01140.x.
10
Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!以青蒿素为基础的联合疗法(ACTs):疟疾治疗的最大希望,但贫困人群难以获得!
Acta Trop. 2005 Sep;95(3):305-15. doi: 10.1016/j.actatropica.2005.06.009.

引用本文的文献

1
Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials.RTS,S/AS01E疫苗用于5至17个月非洲儿童疟疾预防的安全性:随机对照试验的系统评价与荟萃分析
PLOS Glob Public Health. 2025 Jun 16;5(6):e0004387. doi: 10.1371/journal.pgph.0004387. eCollection 2025.
2
Malaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol.撒哈拉以南非洲 5 岁以下儿童疟疾疫苗相关不良事件的系统评价和荟萃分析方案。
BMJ Open. 2023 Oct 4;13(10):e076985. doi: 10.1136/bmjopen-2023-076985.
3
Naturally acquired antibody response to and among indigenous Orang Asli communities in Peninsular Malaysia.
马来西亚半岛原住民族群中针对 和 的自然获得性抗体反应。
Front Cell Infect Microbiol. 2023 Apr 20;13:1165634. doi: 10.3389/fcimb.2023.1165634. eCollection 2023.
4
A Review: Meridianins and Meridianins Derivatives.综述:经络蛋白和经络蛋白衍生物。
Molecules. 2022 Dec 9;27(24):8714. doi: 10.3390/molecules27248714.
5
Survival of eight LLIN brands 6, 12, 24 and 36 months after a mass distribution campaign in rural and urban settings in Senegal.塞内加尔农村和城市地区大规模分发运动 6、12、24 和 36 个月后,八种长效驱虫蚊帐品牌的存活率。
BMC Public Health. 2022 Apr 11;22(1):719. doi: 10.1186/s12889-022-13051-w.
6
Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone.疟疾传播阻断疫苗是否能被高负担社区接受?来自塞拉利昂博城的一项混合方法研究结果。
Malar J. 2021 Apr 13;20(1):183. doi: 10.1186/s12936-021-03723-0.
7
Xylopic acid-amodiaquine and xylopic acid-artesunate combinations are effective in managing malaria in Plasmodium berghei-infected mice.丁香酸-氨酚喹和丁香酸-青蒿琥酯联合用于治疗伯氏疟原虫感染的小鼠疟疾是有效的。
Malar J. 2021 Feb 25;20(1):113. doi: 10.1186/s12936-021-03658-6.
8
Molecular modeling and design of some β-amino alcohol grafted 1,4,5-trisubstituted 1,2,3-triazoles derivatives against chloroquine sensitive, 3D7 strain of .一些β-氨基醇接枝的1,4,5-三取代1,2,3-三唑衍生物针对氯喹敏感的3D7株的分子建模与设计
Heliyon. 2021 Jan 30;7(1):e05924. doi: 10.1016/j.heliyon.2021.e05924. eCollection 2021 Jan.
9
Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review.青蒿素-哌喹治疗非复杂性疟疾的疗效与安全性:一项系统评价
Front Pharmacol. 2020 Sep 11;11:562363. doi: 10.3389/fphar.2020.562363. eCollection 2020.
10
Molecular epidemiological surveillance of Africa and Asia imported malaria in Wuhan, Central China: comparison of diagnostic tools during 2011-2018.分子流行病学监测中非和亚洲输入性疟疾在华中武汉:2011-2018 年诊断工具比较。
Malar J. 2020 Sep 3;19(1):321. doi: 10.1186/s12936-020-03387-2.